

LDI Specialty Drug Pipeline Report July 2010

Estimated Approval	Brand	Generic	Indications	Place In Therapy	Dosage Form
2Q10*	Provenge	sipuleucel-T	Hormone refractory prostate cancer (HRPC)	First in class. Used after failure of other therapies.	IV
2Q10*	Jevtana	cabazitaxel	Advanced prostate cancer	First drug approved specifically for advanced, hormone-refractory prostate cancer that has worsened with other therapies.	IV
2Q10*	Prolia	denosumab	Osteoporosis (postmenopausal, undergoing hormone ablation for either prostate or breast cancer), bone metastases	First in class. Alternative to bisphosphonates.	SC
3Q10	Botox	botulinum toxin type A	Migraine headache	Prevention of chronic migraine.	IM
3Q10	Egrifta	tesamorelin (TH9507)	HIV-associated lipodystrophy	First drug approved for this indication.	SC
3Q10		motavizumab	RSV	Alternative therapy.	IM
3Q10	Monovisc	hyaluronic acid (HA)	Osteoarthritis of the knee	Alternative therapy.	Intra-articular
3Q10	N/A	eribulin mesylate (E731)	Breast cancer	First in class.	IV
3Q10	N/A	Adenovirus Types 4 and 7 Live Oral Vaccines	Adenovirus	Vaccine.	Oral
3Q10	Gilenia	fingolimod (FTY720)	Multiple Sclerosis (MS)	First oral therapy for treatment of Multiple Sclerosis.	Oral
3Q10*	Glassia	Alpha-1 Proteinase Inhibitor	Alpha-1 antitrypsin deficiency	Alternative therapy.	IV (liquid, ready to use)
3Q10	Neuroval	XM02	Severe neutropenia, febrile neutropenia	Would be first bio-similar drug approval in the United States. Will provide competition to Neupogen.	SC
4Q10	azficel-T	autologous human fibroblasts	Wrinkles, acne scars	Cosmetic use.	SC
4Q10	Benlysta	belimumab	Systemic lupus erythematosus (SLE)	First drug specifically designed to treat SLE.	IV
4Q10	Bronchitol	mannitol	Cystic Fibrosis (CF), bronchiectasis	First inhalation powder for CF.	Inhalation powder
4Q10	Ceplene	histamine dihydrochloride	Acute myeloid leukemia (AML) for remission maintenance	Remission maintenance in AML.	SC
4Q10	Davanat	mannose, galactose	Colorectal cancer (CRC)	Alternative therapy.	IV
4Q10	Krystexxa	pegloticase	Gout (treatment-resistant)	Second line therapy.	IV
4Q10	Iluvien	flucinolone acetone	Diabetic macular edema DME	First pharmacologic therapy for DME.	Intravitreal
4Q10	Mylinax or Movectro	cladribine	Multiple Sclerosis (MS)	Oral treatment option for Multiple Sclerosis.	Oral
4Q10	N/A	picoplatin	Small cell lung cancer	Alternative therapy.	IV
4Q10	N/A	nitroglycerin (MQX-503)	Raynaud's disease	Alternative therapy.	Topical
4Q10	Omapro	omacetaxine mepesuccinate	Chronic myelogenous leukemia (CML)	Second line therapy.	SC
4Q10	Upliso	tallglucerase alfa (previously referred to as prGCD-plant cell expressed recombinant glucocerebrosidase)	Gaucher's disease	Alternative therapy.	IV
4Q10	Zactima	vandetanib	Non-small cell lung cancer (NSCLC)	Second line therapy.	oral
4Q10	Zalbin	albinterferon alfa-2b	Hepatitis C	Alternative therapy.	SC

* Recent FDA approval.